NVCR News and Press, NovoCure Limited From 11/26/22

Many companies like to claim that they have revolutionary, game-changing products. Few live up to the hype. Novocure (NASDAQ: NVCR) could be an exception. Its tumor-treating fields (TTFields) therapy uses electrical signals to disrupt the division of tumor cells. But just be...

Novocure (NASDAQ: NVCR) announced today it will participate in the 34 th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside c...

Health economics and outcomes research showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in a large commercially insured population The largest safety dataset to date of more than 23,000 patients reinforced that TTField...

Novocure chose Montreal because of its innovative culture, world-class universities and hospitals, access to top talent and quality of life Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. No...

New arrays are lighter, thinner and more flexible than current commercial arrays and have the potential to optimize Tumor Treating Fields dose Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, design...

Some investors prefer boring stocks. That's completely understandable. Boring stocks often deliver the best long-term returns. They're like the tortoise in Aesop's classic fable about the hare and the tortoise. But other investors seek more excitement. They know that hares win plenty of...

At the heart of the medical device space isn’t just new technologies for diagnostics but also substitutes for potentially addictive and life-destroying drugs. Anything you can do with physical-external stimuli instead of pills that impact the brain is possibly a life-changing option fo...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...

Summary A bear market is a highly opportunistic time for you to average down on fundamentally robust companies. NovoCure is a phenomenal growth stock that recently transitioned into a stalwart. Though NovoCure posted stellar growth in the previous few years, there are still su...

Little Orphan Annie had it right: The sun will come out tomorrow. Although we're in a bear market now, stocks will rebound in time. We asked three Motley Fool contributors which stocks they're especially optimistic about. Here's why they think that Ginkgo Bioworks Holdings (NYSE: ...